Delving into the Latest Updates on Zentralklinik Bad Berka GmbH with Synapse

Overview

Tags

Other Diseases

Diagnostic radiopharmaceuticals

Peptide Conjugate Radionuclide

Disease domain score

A glimpse into the focused therapeutic areas

No Data

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Top 5 Drug Type	Count

Diagnostic radiopharmaceuticals	1
Peptide Conjugate Radionuclide	1

Top 5 Target	Count

SSTR(Somatostatin receptor)	1

The German Quality Network Sepsis is an association trying to improve quality of care for patients with sepsis, severe sepsis and septic shock or being in risc thereof.
The icosmos trial investigates the impact on the use of routine data, a risk adjustment algorithm and feedback to all hospitals as well as a structured implementation for regular screening for deteriorating patients, and education on in-hospital mortality.

Start Date01 Aug 2015

Sponsor / Collaborator

Klinikum Nürnberg

[+9]

DRKS00004247 / RecruitingNot Applicable

Impact of different positive end-expiratory pressure (PEEP) with low tidal volumes during one-ventilation on lung mechanics, gas exchange, and hemodynamics

Start Date15 Aug 2012

Sponsor / Collaborator

Zentralklinik Bad Berka GmbH

NCT00815620 / CompletedNot Applicable

Best Therapy for Patients With Neuroendocrine Tumors

A prospective observational study containing three arms comprising different therapeutic measures to treat patients with neuroendocrine tumors in advanced stages. The therapy arms include local ablative therapy such as TACE or SIRT, surgery and RFA with peptide receptor radiotherapy.

Start Date01 Nov 2008

Sponsor / Collaborator

Zentralklinik Bad Berka GmbH

100 Clinical Results associated with Zentralklinik Bad Berka GmbH

Login to view more data

0 Patents (Medical) associated with Zentralklinik Bad Berka GmbH

Login to view more data

155

Literatures (Medical) associated with Zentralklinik Bad Berka GmbH

01 Aug 2024·Journal of the American College of Cardiology

Real-World 1-Year Results of Tricuspid Edge-to-Edge Repair From the bRIGHT Study

Article

Author: Schmeisser, Alexander ; Atmowihardjo, Iskandar ; Nickenig, Georg ; von Bardeleben, Ralph Stephan ; Lubos, Edith ; Estevez-Loureiro, Rodrigo ; Peterman, Kelli ; Möllmann, Helge ; Schmitz, Thomas ; Bekeredjian, Raffi ; Lurz, Philipp ; Donal, Erwan ; Heitkemper, Megan ; Lapp, Harald ; Rommel, Karl-Philipp

BACKGROUNDSevere tricuspid regurgitation (TR) is known to be associated with poor quality of life and increased risk of death when left untreated.OBJECTIVESWe sought to report the 1-year clinical outcomes of subjects treated by tricuspid transcatheter edge-to-edge repair (TEER) with the TriClip system (Abbott Cardiovascular) in a contemporary real-world setting.METHODSThe bRIGHT (An Observational Real-World Study Evaluating Severe Tricuspid Regurgitation Patients Treated With the Abbott TriClip Device) postapproval study is a prospective, single-arm, open-label, multicenter postmarket registry conducted at 26 sites in Europe, with central event adjudication and echocardiographic core-laboratory assessment.RESULTSEnrolled subjects (n = 511) were elderly (79 ± 7 years) with significant comorbidities. A total of 88% had baseline massive or torrential TR, and 80% of subjects were in NYHA functional class III/IV. TR was reduced to moderate or less in 81% at 1 year. Significant improvements in NYHA functional class (21% to 75% I/II, P < 0.0001) and Kansas City Cardiomyopathy Questionnaire (KCCQ) score (19 ± 26-point improvement, P <0.0001) were observed at 1 year. One-year mortality was significantly lower in subjects who achieved moderate or lower TR at 30 days; however, there was no difference in mortality among subjects who achieved moderate, mild, or trace TR at 30 days. In addition to TR reduction at 30 days, baseline serum creatinine and baseline right ventricular tricuspid annular plane systolic excursion (RV TAPSE) were independently associated with mortality at 1 year (OR: 2.169; 95% CI: 1.494-3.147; P < 0.0001; OR: 0.636; 95% CI: 0.415-0.974; P = 0.0375). Mortality was not associated with baseline TR grade or with center volume.CONCLUSIONSTricuspid TEER using the TriClip system was safe and effective through 1 year for subjects with significant TR and advanced disease in a diverse real-world population. (An Observational Real-world Study Evaluating Severe Tricuspid Regurgitation Patients Treated With the Abbott TriClip Device [bRIGHT]; NCT04483089).

01 Aug 2024·Aktuelle Urologie

Invasive Neurostimulation in der Neuro-Urologie: State of the Art

Review

Author: Kurze, Ines ; van Ophoven, Arndt ; Böthig, Ralf

01 Aug 2024·Aktuelle Urologie

Stellenwert der neuro-urologischen Betreuung von Patienten mit Rückenmarkverletzungen/-erkrankungen

Review

Author: Kurze, Ines ; Wöllner, Jens

100 Deals associated with Zentralklinik Bad Berka GmbH

Login to view more data

100 Translational Medicine associated with Zentralklinik Bad Berka GmbH

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

6

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

44Sc-edotreotide ( SSTR )	Diagnostic agents More	Clinical
Theranost 68Ga-RGD ( αvβ3 )	Contrast agents More	Discontinued
IPN-01087(3B Pharmaceuticals GmbH) ( NTSR1 )	Ewing Sarcoma More	Pending
68Ga-ABY-002 ( HER2 )	HER2 Positive Breast Cancer More	Pending
68Ga-sarabesin-3 ( GRP )	Prostatic Cancer More	Pending